TomoIsLearning
Pls donate to me a maxilla
- Joined
- Mar 25, 2026
- Posts
- 166
- Reputation
- 78
KISSPEPTIN
The Peptide Above GnRH That Nobody Talks About
The Peptide Above GnRH That Nobody Talks About
Most guys in the PCT space consider the HPG axis to begin with GnRH. Hypothalamus secretes GnRH, pituitary secretes LH and FSH, testes produce testosterone. That's where the discussion stops for most people on this forum.
But GnRH doesn't just release itself. Something controls it. And almost nobody talks about what that something actually is.
That something is kisspeptin.
What It Actually Is
Kisspeptin is a neuropeptide produced by neurons in the hypothalamus. Binds to a receptor called KISS1R and directly triggers GnRH release. Without kisspeptin firing GnRH doesn't pulse. Without GnRH pulsing the entire HPG axis stays silent.
Code:
HYPOTHALAMUS
↓ (Kisspeptin triggers this)
GnRH pulse
↓
PITUITARY
↓ (releases)
LH + FSH
↓
TESTES
↓ (produces)
TESTOSTERONE
↑_________________|
(negative feedback loop)This is why it's being heavily researched right now for hypogonadotropic hypogonadism and infertility. Fixing the problem at the source is more physiological than patching it downstream.
What Shuts It Down
Testosterone and estrogen both feed back negatively on kisspeptin neurons. That's actually how the HPG axis self-regulates. High testosterone suppresses kisspeptin, kisspeptin drops, GnRH drops, LH drops, testosterone drops. Classic negative feedback loop.
Run exogenous testosterone and this feedback loop gets absolutely hammered. Supraphysiological levels crush kisspeptin activity completely. GnRH neurons go quiet. The whole cascade shuts off. That's HPTA suppression explained at the actual top of the chain, not halfway down it.
SERMs like nolvadex and clomid work by blocking estrogen receptors at the hypothalamus and pituitary. This partially relieves the negative feedback on kisspeptin neurons. But they're working around kisspeptin not through it. There's a meaningful difference between those two things.
Does It Actually Work For Recovery
Yes. And the research is more solid than most people realize.
A 2010 study in the Journal of Clinical Endocrinology and Metabolism showed kisspeptin-54 administration in healthy men produced significant LH pulses. The HPG axis responded directly to kisspeptin stimulation even under conditions of partial suppression.
A 2013 study in men with hypogonadotropic hypogonadism showed repeated kisspeptin administration restored pulsatile LH secretion. Significant because hypogonadotropic hypogonadism shares key features with post-cycle HPTA suppression.
Research from Jayasena et al. demonstrated kisspeptin administration increased testosterone in men with low gonadotropin levels by restoring the upstream GnRH signal rather than bypassing it.
A 2013 study in men with hypogonadotropic hypogonadism showed repeated kisspeptin administration restored pulsatile LH secretion. Significant because hypogonadotropic hypogonadism shares key features with post-cycle HPTA suppression.
Research from Jayasena et al. demonstrated kisspeptin administration increased testosterone in men with low gonadotropin levels by restoring the upstream GnRH signal rather than bypassing it.
The practical problem is the same one gonadorelin has. Extremely short half life. Kisspeptin-54 and kisspeptin-10 are the research forms. Both clear fast. Pulsatile administration needed to avoid receptor desensitization. Twice weekly pinning accomplishes very little here unlike HCG where that frequency actually works.
And unlike gonadorelin which is approved for compounding in most US states, kisspeptin is not. California blocks it outright. Most compounding pharmacies won't touch it. That's the real wall right now.
Kisspeptin vs Gonadorelin
Both work upstream of LH and FSH. Both more physiological than HCG. Both have the short half life problem.
| Factor | Kisspeptin | Gonadorelin |
| Acts on | Hypothalamus (above GnRH) | Pituitary (replaces GnRH) |
| Stimulates GnRH | Yes, naturally | Replaces it directly |
| Stimulates LH | Yes, via GnRH | Yes, via pituitary |
| Stimulates FSH | Yes | Yes |
| Half life | Very short (~minutes) | ~2-4 minutes |
| Compounding approved | No | Yes (most states) |
| Research in AAS recovery | Limited | Moderate |
| Sourcing | Very difficult | Easier |
| Physiological hierarchy | Higher | One step below |
Should You Run It Right Now
No. Not as a standalone. Sourcing is retardedly difficult, dosing is complicated, and AAS recovery research is thin compared to gonadorelin or standard SERMs.
Kisspeptin analogues with significantly longer half lives are in active development. TAK-448 and MVT-602 are in clinical trials showing extended activity compared to native kisspeptin. Once a longer acting analogue becomes accessible the calculus changes completely.
A compound that restores natural pulsatile GnRH signaling from the top of the chain without requiring a pump or daily injections would be a genuine upgrade over everything currently used in PCT. That's where this is heading.
A compound that restores natural pulsatile GnRH signaling from the top of the chain without requiring a pump or daily injections would be a genuine upgrade over everything currently used in PCT. That's where this is heading.
